Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C32H55N4O |
| Molecular Weight | 511.8053 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 1 |
SHOW SMILES / InChI
SMILES
CCCCCCCCCCCCCCCC[N+](C)(C)CCN(CC1=CC=C(OC)C=C1)C2=NC=CC=N2
InChI
InChIKey=IOYZYMQFUSNATM-UHFFFAOYSA-N
InChI=1S/C32H55N4O/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-27-36(2,3)28-26-35(32-33-24-19-25-34-32)29-30-20-22-31(37-4)23-21-30/h19-25H,5-18,26-29H2,1-4H3/q+1
Thonzonium Bromide is a cationic surface-active compound. As an additive to pharmacologic formulations, thonzonium bromide causes dispersion and penetration of cellular debris and exudate, thereby promoting tissue contact of the administered medication. Thonzonium
bromide is a component of FDA-approved Coly-Mycin S Otic, used for treating infections of the ear caused by certain bacteria. It has being shown that Thonzonium bromide inhibits RANKL-induced osteoclast formation and bone resorption in vitro and prevents LPS-induced bone loss in vivo, suggesting that Thonzonium bromide might be a useful alternative therapy in preventing or treating osteolytic diseases..
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0036035 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | COLY-MYCIN S Approved UseCortisporin®-TC Otic Suspension is indicated for the treatment of superficial bacterial infections of the external auditory canal, caused by organisms susceptible to the action of the antibiotics; and for the treatment of infections of mastoidectomy and fenestration cavities, caused by organisms susceptible to the antibiotics. Launch Date-2.40710402E11 |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Thermal decomposition of thonzonium bromide. | 1986 Oct |
|
| Inhibitors of V-ATPase proton transport reveal uncoupling functions of tether linking cytosolic and membrane domains of V0 subunit a (Vph1p). | 2012 Mar 23 |
|
| Thonzonium bromide inhibits RANKL-induced osteoclast formation and bone resorption in vitro and prevents LPS-induced bone loss in vivo. | 2016 Mar 15 |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID8048232
Created by
admin on Fri Dec 15 15:47:42 UTC 2023 , Edited by admin on Fri Dec 15 15:47:42 UTC 2023
|
PRIMARY | |||
|
Z05ZE98FV8
Created by
admin on Fri Dec 15 15:47:42 UTC 2023 , Edited by admin on Fri Dec 15 15:47:42 UTC 2023
|
PRIMARY | |||
|
237058
Created by
admin on Fri Dec 15 15:47:42 UTC 2023 , Edited by admin on Fri Dec 15 15:47:42 UTC 2023
|
PRIMARY | RxNorm | ||
|
5456
Created by
admin on Fri Dec 15 15:47:42 UTC 2023 , Edited by admin on Fri Dec 15 15:47:42 UTC 2023
|
PRIMARY | |||
|
DB09552
Created by
admin on Fri Dec 15 15:47:42 UTC 2023 , Edited by admin on Fri Dec 15 15:47:42 UTC 2023
|
PRIMARY | |||
|
4605
Created by
admin on Fri Dec 15 15:47:42 UTC 2023 , Edited by admin on Fri Dec 15 15:47:42 UTC 2023
|
PRIMARY | |||
|
25466-36-8
Created by
admin on Fri Dec 15 15:47:42 UTC 2023 , Edited by admin on Fri Dec 15 15:47:42 UTC 2023
|
PRIMARY | |||
|
Z05ZE98FV8
Created by
admin on Fri Dec 15 15:47:42 UTC 2023 , Edited by admin on Fri Dec 15 15:47:42 UTC 2023
|
PRIMARY | |||
|
Thonzonium
Created by
admin on Fri Dec 15 15:47:42 UTC 2023 , Edited by admin on Fri Dec 15 15:47:42 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
